BioSpace News Archive

According to Nova one advisor, the global Fibrinogen Concentrates market size is expected to hit around USD 6.89 billion by 2030 from valued at USD 2.98 billion in 2021 and growing at a CAGR of 8.1% from 2022 to 2030.

According to Nova one advisor, the global Membrane Filtration market was valued at USD 16 .9 billion in 2021 and it is expected to hit around USD 36.9 billion by 2030 with a CAGR of 9.29% during the forecast period 2022 to 2030.

The global Respiratory Virus Infection Drugs market gathered revenue around USD 39.2 Billion in 2020 and market is set to grow USD 81.2 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 6.9% during the prediction period 2021 to 2027.

According to Nova one advisor, the global Molecular Diagnostics market was valued at USD 25.2 billion in 2022and it is expected to hit around USD 47.9 billion by 2030 with a CAGR of 14.1% during the forecast period 2022 to 2030.

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2022 of $0.98 per share on outstanding common stock.

NKGen Biotech, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to commence a Phase 1, open-label, dose-escalation study of its cryopreserved “off-the-shelf” allogeneic blood-derived NK cell therapy.

Tampa General Hospital, in partnership with Florida Urology Partners, are the first in the U.S. to offer a next-generation technology that recently received U.S. Food and Drug Administration 510 clearance.

DICE Therapeutics, Inc. announced the closing on October 17, 2022 of its previously announced upsized underwritten public offering of 9,452,054 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,232,876 additional shares, at a public offering price of $36.50 per share.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, today announced that it will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022.

Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has granted approval for the use of Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.